FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1974188826> ?p ?o ?g. }

• W1974188826 abstract "Anemia is common in cancer patients during chemotherapy. The study discussed in this article was primarily designed to assess the effects of epoetin alfa on transfusion requirements, hematopoietic response, quality of life (QOL), and safety in cancer patients receiving nonplatinum-based chemotherapy under randomized, double-blind, placebo-controlled conditions. Over the course of the study, a growing body of evidence from other studies suggested an association between low hemoglobin (Hb) levels and poorer prognosis in patients receiving radiotherapy, chemotherapy or combination therapies. Therefore, prior to unblinding, the study protocol was amended to explore a possible relationship between increased Hb levels and survival by collecting survival data for 12 months after the last patient completed the study. A total of 375 patients with solid tumors or nonmyeloid hematologic malignancies (Hb ≤10.5 g/dl or Hb >10.5 g/dl but ≤ 12.0 g/dl with a decrease of ≥ 1.5 g/dl per cycle or month since starting chemotherapy) were randomized 2:1 to receive 150-300 IU/kg epoetin alfa (n=251) or placebo (n= 124) subcutaneously three times weekly for 12-24 weeks, or for 3-6 chemotherapy cycles plus 4 weeks after chemotherapy. The primary efficacy endpoint was the proportion of patients transfused. Secondary endpoints included changes in Hb level and QOL measurements. Hematopoietic response in terms of the proportion of responders (patients whose Hb level increased by at least 2 g/dl during the study without transfusion) and correctors (patients who achieved an Hb level of at least 12 g/dl during the study without transfusion) were also determined. Compared with placebo, epoetin alfa significantly decreased transfusion requirements (P=0.0057) and increased Hb levels (P <0.001). There were significantly more responders and correctors in the epoetin alfa group than in the placebo group (P <0.001 for both). Epoetin alfa also provided significantly greater improvements (P <0.01) in all primary cancer- and anemiaspecific QOL domains, including energy level, ability to do daily activities, fatigue and overall QOL score. Adverse events were comparable between treatment groups. Median survival times were 17 months for epoetin alfa-treated patients and 11 months for placebo-treated patients. Kaplan-Meier 12-month survival estimates were 60% for epoetin alfa-treated patients and 49% for placebo-treated patients. The log-rank test indicated a trend in overall survival for epoetin alfa (P=0.13). These survival results must be interpreted with caution because the study was not powered to assess survival, nor was it controlled for stage of disease, bone marrow involvement, intensity of chemotherapy or disease progression. This study allowed regulatory approval of epoetin alfa for treatment of non-cisplatin-induced chemotherapy-related anemia. Epoetin alfa also decreases the impact of anemia on QOL, and may improve survival of cancer patients." @default.
• W1974188826 created "2016-06-24" @default.
• W1974188826 creator A5031668702 @default.
• W1974188826 creator A5032502229 @default.
• W1974188826 creator A5033285318 @default.
• W1974188826 creator A5036885611 @default.
• W1974188826 creator A5061483613 @default.
• W1974188826 creator A5070704228 @default.
• W1974188826 date "2004-02-01" @default.
• W1974188826 modified "2023-10-16" @default.
• W1974188826 title "Is there a possible survival benefit to increasing hemoglobin levels with epoetin alfa during chemotherapy?" @default.
• W1974188826 cites W1497292368 @default.
• W1974188826 cites W1503662436 @default.
• W1974188826 cites W1821554592 @default.
• W1974188826 cites W1867073577 @default.
• W1974188826 cites W1884165293 @default.
• W1974188826 cites W1885881044 @default.
• W1974188826 cites W1919092210 @default.
• W1974188826 cites W1970997581 @default.
• W1974188826 cites W1977280396 @default.
• W1974188826 cites W2014481700 @default.
• W1974188826 cites W2015276413 @default.
• W1974188826 cites W2023281083 @default.
• W1974188826 cites W2048125117 @default.
• W1974188826 cites W2079906459 @default.
• W1974188826 cites W2094963379 @default.
• W1974188826 cites W2115012618 @default.
• W1974188826 cites W2116150717 @default.
• W1974188826 cites W2125096092 @default.
• W1974188826 cites W2125257427 @default.
• W1974188826 cites W2139331374 @default.
• W1974188826 cites W2220352889 @default.
• W1974188826 cites W2268186367 @default.
• W1974188826 cites W2329804409 @default.
• W1974188826 cites W2469073599 @default.
• W1974188826 cites W2478225583 @default.
• W1974188826 cites W2995133996 @default.
• W1974188826 doi "https://doi.org/10.1016/s1359-6349(03)00104-6" @default.
• W1974188826 hasPublicationYear "2004" @default.
• W1974188826 type Work @default.
• W1974188826 sameAs 1974188826 @default.
• W1974188826 citedByCount "3" @default.
• W1974188826 countsByYear W19741888262016 @default.
• W1974188826 crossrefType "journal-article" @default.
• W1974188826 hasAuthorship W1974188826A5031668702 @default.
• W1974188826 hasAuthorship W1974188826A5032502229 @default.
• W1974188826 hasAuthorship W1974188826A5033285318 @default.
• W1974188826 hasAuthorship W1974188826A5036885611 @default.
• W1974188826 hasAuthorship W1974188826A5061483613 @default.
• W1974188826 hasAuthorship W1974188826A5070704228 @default.
• W1974188826 hasBestOaLocation W19741888261 @default.
• W1974188826 hasConcept C121608353 @default.
• W1974188826 hasConcept C126322002 @default.
• W1974188826 hasConcept C141071460 @default.
• W1974188826 hasConcept C142724271 @default.
• W1974188826 hasConcept C143998085 @default.
• W1974188826 hasConcept C168563851 @default.
• W1974188826 hasConcept C203092338 @default.
• W1974188826 hasConcept C204787440 @default.
• W1974188826 hasConcept C27081682 @default.
• W1974188826 hasConcept C2776164570 @default.
• W1974188826 hasConcept C2776694085 @default.
• W1974188826 hasConcept C2778248108 @default.
• W1974188826 hasConcept C2778917026 @default.
• W1974188826 hasConcept C71924100 @default.
• W1974188826 hasConcept C90924648 @default.
• W1974188826 hasConceptScore W1974188826C121608353 @default.
• W1974188826 hasConceptScore W1974188826C126322002 @default.
• W1974188826 hasConceptScore W1974188826C141071460 @default.
• W1974188826 hasConceptScore W1974188826C142724271 @default.
• W1974188826 hasConceptScore W1974188826C143998085 @default.
• W1974188826 hasConceptScore W1974188826C168563851 @default.
• W1974188826 hasConceptScore W1974188826C203092338 @default.
• W1974188826 hasConceptScore W1974188826C204787440 @default.
• W1974188826 hasConceptScore W1974188826C27081682 @default.
• W1974188826 hasConceptScore W1974188826C2776164570 @default.
• W1974188826 hasConceptScore W1974188826C2776694085 @default.
• W1974188826 hasConceptScore W1974188826C2778248108 @default.
• W1974188826 hasConceptScore W1974188826C2778917026 @default.
• W1974188826 hasConceptScore W1974188826C71924100 @default.
• W1974188826 hasConceptScore W1974188826C90924648 @default.
• W1974188826 hasLocation W19741888261 @default.
• W1974188826 hasOpenAccess W1974188826 @default.
• W1974188826 hasPrimaryLocation W19741888261 @default.
• W1974188826 hasRelatedWork W2058251329 @default.
• W1974188826 hasRelatedWork W2060861099 @default.
• W1974188826 hasRelatedWork W2371666691 @default.
• W1974188826 hasRelatedWork W2378355431 @default.
• W1974188826 hasRelatedWork W2926546306 @default.
• W1974188826 hasRelatedWork W3139593660 @default.
• W1974188826 hasRelatedWork W3143258082 @default.
• W1974188826 hasRelatedWork W3198647362 @default.
• W1974188826 hasRelatedWork W4242900507 @default.
• W1974188826 hasRelatedWork W7677460 @default.
• W1974188826 isParatext "false" @default.
• W1974188826 isRetracted "false" @default.
• W1974188826 magId "1974188826" @default.
• W1974188826 workType "article" @default.